Lung Cancer Biomarkers and Screening
- Conditions
- Lung Cancer
- Registration Number
- NCT00301119
- Lead Sponsor
- NYU Langone Health
- Brief Summary
RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer.
PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.
- Detailed Description
OBJECTIVES:
* Identify and validate biomarkers for the early detection of lung cancer in individuals at low- or high-risk for smoking-related cancers.
* Identify preneoplastic cellular changes and lesions in these patients.
OUTLINE: Participants are stratified according to lung cancer risk status (with or without increased risk).
Group 1 (screening cohort): Participants complete a questionnaire and undergo pulmonary function testing, multidetector chest CT scan, sputum induction, and phlebotomy.
Group 2 (rule-out lung cancer): Participants complete the same questionnaire and undergo the same tests and scans as in group 1. Some participants may undergo fiberoptic bronchoscopy based upon CT scan results with transbronchial or endobronchial biopsies. Some participants may undergo lung resection. Tissue samples are collected from surgery or biopsy.
PROJECTED ACCRUAL: A total of participants will be accrued for this study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 9350
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Lung cancer diagnosis as measured by CT scan findings and pathology findings annually 07/01/2015
- Secondary Outcome Measures
Name Time Method Precancerous lung nodules as measured by CT scan findings and pathology findings annually 07/01/2015
Trial Locations
- Locations (1)
NYU Cancer Institute at New York University Medical Center
🇺🇸New York, New York, United States